Super Bowl Victory ...
Health Care: Drugs
Dendreon Corp (DNDN: NASDAQ)
$15.27 -0.69 | -4.32%
02/08/12 - 04:00 PM ET
13.02M / 8.90M
Vol / Avg. Vol:16.00 / 15.96
Open / Prev. Close:15.12 - 16.28
Today's Range:6.46 - 43.96
52 Wk Range:100.92%
Performance YTD:TheStreet Rating:
Portfolios with DNDN
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- ContributorRelative Strength Trades fo...
- Userchrisnash69 Portfolio 1
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- UserFair Employee - Regular Guy
- Contributor5 Stocks Under-$10 Setting ...
- Contributor13 Biotech Stocks Bought an...
- UserPortfolio A
Latest DNDN Headlines from TheStreet
- Will Greece Indigestion Take Down Markets?
02.07.12 | 07:02 am - 7 Relative Strength Stocks to Beat the Market 02.02.12 | 12:02 pm
- 8 Stocks Rising on Huge Volume 02.01.12 | 02:02 pm
- Medivation's Prostate Cancer Drug: Survival Benefit With Low Seizure Risk 01.31.12 | 05:01 pm
- Daily Recap of the Charts Jan. 25 01.25.12 | 04:01 pm
- Analysts' Actions: BHI, MCD, MRO, KMB 01.25.12 | 08:01 am
- Find Buying Opportunities as Markets Consolidate 01.25.12 | 08:01 am
- Daily Recap of the Charts Jan. 24 01.24.12 | 04:01 pm
- Aastrom CEO: Financing Close to Completion 01.18.12 | 08:01 am
- Dendreon's Management Presents At J.P. Morgan Healthcare Conference (Transcript) 01.09.12 | 09:01 pm
Press Releases for DNDN
- Dendreon To Host Conference Call On February 27 To Announce Fourth Quarter And Year-End Financial Results And Webcast Presentations At Upcoming Conferences - Business Wire 02.01.12 | 09:02 pm
- Dendreon Announces CEO And Chairman Succession Plan - Business Wire 02.01.12 | 06:02 am
- Dendreon Announces Presentation Of PROVENGE Data At The ASCO 2012 Genitourinary Cancers Symposium - Business Wire 01.31.12 | 06:01 pm
- Dendreon Announces Fourth Quarter Revenues And Update On Commercialization - Business Wire 01.05.12 | 09:01 am
- Dendreon Announces Webcast Presentation At J.P. Morgan Healthcare Conference - Business Wire 01.04.12 | 09:01 pm
- Dendreon Agrees To Sell VICTRELIS™ (boceprevir) Royalty Interest For $125 Million - Business Wire 12.06.11 | 12:12 pm
- Dendreon Announces Webcast Presentation At Upcoming Conferences - Business Wire 11.22.11 | 04:11 pm
- Dendreon Announces The Centers For Medicare And Medicaid Services (CMS) Will Now Cover Infusion Costs Associated With The Administration Of PROVENGE - Business Wire 11.21.11 | 08:11 am
- Dendreon Announces Election Of Dennis M. Fenton To Board Of Directors - Business Wire 11.08.11 | 08:11 am
- Dendreon Reports Third Quarter 2011 Financial Results - Business Wire 11.02.11 | 04:11 pm
Partner Headlines for DNDN
- Company News for February 2, 2012 - Corporate Summary - Zacks 02.02.12 | 10:02 am
- Momentum Trading: These 6 Stocks Are Up More Than 50% Already in 2012 - Benzinga 01.27.12 | 03:01 pm
- Biopharma Stocks To Watch This Week - Seeking Alpha 01.19.12 | 09:01 am
- Another Revival Could Be In Store For Immunocellular Therapeutics - Seeking Alpha 01.18.12 | 09:01 am
- Oink Oink: Profit From The Return Of Swine Flu - Benzinga 01.12.12 | 01:01 pm
- Why ImmunoCellular Therapeutics Is Different - Seeking Alpha 01.11.12 | 08:01 am
- Stocks To Watch This Week - Seeking Alpha 01.10.12 | 08:01 am
- Did John 3:16 Predict These Companies' Successes? - Benzinga 01.09.12 | 01:01 pm
- Biotech Investors Buoyed By Signs Of Speedier Drug Launches - Seeking Alpha 01.09.12 | 08:01 am
- Stock charts to watch next week - Benzinga 01.06.12 | 05:01 pm
